| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lutetium lu 177 dotatate | somatostatin receptor type 1 | small molecule | Successful target | TTD , drugbank , DGIDB | Neuroendocrine Tumors[MeSHID:D018358] Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650] Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| lutetium lu 177 dotatate | somatostatin receptor type 2 | small molecule | NA | drugbank | Neuroendocrine Tumors[MeSHID:D018358] Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650] Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| lutetium lu 177 dotatate | somatostatin receptor type 3 | small molecule | NA | drugbank | Neuroendocrine Tumors[MeSHID:D018358] Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650] Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| lutetium lu 177 dotatate | somatostatin receptor type 4 | small molecule | NA | drugbank | Neuroendocrine Tumors[MeSHID:D018358] Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650] Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| lutetium lu 177 dotatate | somatostatin receptor type 5 | small molecule | NA | drugbank | Neuroendocrine Tumors[MeSHID:D018358] Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650] Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| click here to return to the previous page | ||||||||